Acute Tonsillitis Clinical Trial
Official title:
A Multicenter, Randomized, Open, Comparative Study of Efficacy, Safety and Tolerability of Imupret Application in the Concept of Delayed Prescription of Antibiotics in Children, Aged 6-12 With Acute Tonsillitis
NCT number | NCT04537819 |
Other study ID # | ATi-2 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 20, 2019 |
Est. completion date | March 25, 2020 |
Verified date | August 2020 |
Source | Ivano-Frankivsk National Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The problem of acute tonsillitis (AT) is one of the most urgent in modern clinical medicine.
The prevalence of pathology ranges from 2 to 15% of the total population.
AT (ICD J03.0-J03.9) in most cases is due to viral infections. Bacterial acute tonsillitis
occurs in immunocompetent children in 20-30% of cases.
To determine the indications for antibacterial therapy, the Mclsaac scale is a commonly used
tool for decision. This scale is used to classify patients according to their symptoms and to
determine the patients for whom antibiotic therapy is not indicated.
Thus, in most cases of acute tonsillitis (even if there are 4-5 points according to the
scale), it has to be taken into account that there is a low probability of the presence of
GABS. Therefore, there are no unconditional indications for the prescription of antibiotics.
Unjustified antibiotic therapy of AT plays a significant role in the formation of antibiotic
resistance.
To prevent unjustified prescription of antibiotics, a therapeutic concept of delayed
administration is proposed. A patient with AT is prescribed treatment with antibiotics in a
delayed manner. In the absence of a positive effect within 36-48 hours from the beginning of
treatment with Imupret, the antibacterial therapy is started. The advantage of deferred
antibiotic prescription is, that a higher number of patients and doctors, awaiting antibiotic
therapy, may be more agreeable with this way of treatment than with a complete rejection of
the antibiotic's prescription. So delayed use of antibiotics is an important treatment
strategy to reduce the number of unreasonable prescriptions of antibiotics.
Considering this fact, it becomes necessary to use drugs with a complex effect and
evidence-based efficacy base for acute tonsillitis. At the moment, there is an insignificant
evidence base for the application of the phytoneering drug Imupret in acute tonsillitis. The
spectrum of its pharmacological properties includes antiviral, antibacterial,
anti-inflammatory, and immunomodulating effects. The combination of these properties makes it
possible to influence practically all parts of acute tonsillitis. The already existing
studies were not conducted under GCP conditions. Confirmation of the high effectiveness of
Imupret in the treatment of acute tonsillitis would serve as a rationale for optimizing the
treatment regimen of this nosology and recommendations for the inclusion of the drug in
national guidelines.
Status | Completed |
Enrollment | 200 |
Est. completion date | March 25, 2020 |
Est. primary completion date | January 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Children (males/females), 6 - 12 years old, with severe acute tonsillitis. - Possibility to initiate therapy within 72 hours since the onset of the disease symptoms. - Score 4-5 according to McIsaac Scale. - Patient's and (or) one of his/her parents' willingness and ability to fulfil the requirements of the Study Protocol. - Signed informed consent of the patient and (or) his/her parents for participation in the study. Exclusion Criteria: - Score -1 to 3 according to McIsaac Scale. - Indication for hospitalization, including: - purulent complications (peritonsillar abscess and others); - severe general condition. - Indication for immediate initiation of systemic antibiotic therapy - patients at risk of developing severe complications, including e.g. clinically relevant concomitant diseases of heart, lungs, kidneys, liver, neuromuscular apparatus, cancer diseases, immunosuppression, diabetes mellitus, cystic fibrosis. - suspected infectious mononucleosis (by clinical signs); - use of systemic antibacterial or antifungal agents, systemic glucocorticosteroids, cytostatics, immunomodulatory drugs, "interferons" or interferon derivatives during the last 14 days prior to inclusion; - presence of haemorrhagic or pronounced necrotic process in oral cavity or pharynx, including the lymphoid ring. - Intolerability or individual hypersensitivity to any of the study drug ingredients and the reference treatment scheme. |
Country | Name | City | State |
---|---|---|---|
Ukraine | Ivano-Frankivsk National Medical University | Ivano-Frankivs'k | Ivano-Frankivsk |
Lead Sponsor | Collaborator |
---|---|
Ivano-Frankivsk National Medical University | Bionorica SE |
Ukraine,
Abdulkerimov KT, Kartashova KI, Davydov RS, Abdulkerimov ZK, Kolesnikova AV, Yusupova DR. [The comparative evaluation of the effectiveness of the treatment of the patients presenting with the sub-compensated form of chronic tonsillitis making use of the a — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | - Changes in the severity of each symptom (complaint). | - Changes in the severity of each symptom (complaint; 0 - 4 points per symptom) that is part of the Acute tonsilitis severity scale of tonsillitis manifestations, up to 1 point or less. This variable is dichotomous, with the categories "treatment effective" and "treatment not effective". | Day 1; 3; 5; 10; 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03704506 -
Registration of the Study of Reyanning Mixture
|
Phase 4 | |
Active, not recruiting |
NCT04682964 -
Bacteriophage Therapy in Tonsillitis
|
Phase 3 | |
Not yet recruiting |
NCT02715037 -
Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis
|
N/A | |
Completed |
NCT01363531 -
Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies
|
Phase 4 | |
Recruiting |
NCT03134443 -
Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Tonsillitis
|
Phase 4 |